Glucotrack (GCTK) EBIT (2016 - 2020)
Historic EBIT for Glucotrack (GCTK) over the last 7 years, with Q4 2020 value amounting to -$878000.0.
- Glucotrack's EBIT fell 11370.63% to -$878000.0 in Q4 2020 from the same period last year, while for Dec 2020 it was -$3.1 million, marking a year-over-year decrease of 15637.04%. This contributed to the annual value of -$7.1 million for FY2023, which is N/A changed from last year.
- Per Glucotrack's latest filing, its EBIT stood at -$878000.0 for Q4 2020, which was down 11370.63% from -$887000.0 recorded in Q3 2020.
- In the past 5 years, Glucotrack's EBIT registered a high of $18.5 million during Q4 2017, and its lowest value of -$2.6 million during Q3 2017.
- For the 5-year period, Glucotrack's EBIT averaged around $491216.6, with its median value being -$937389.5 (2019).
- Its EBIT has fluctuated over the past 5 years, first surged by 149760.6% in 2017, then tumbled by 17375.23% in 2020.
- Quarter analysis of 5 years shows Glucotrack's EBIT stood at -$1.3 million in 2016, then skyrocketed by 1497.61% to $18.5 million in 2017, then tumbled by 105.48% to -$1.0 million in 2018, then skyrocketed by 733.34% to $6.4 million in 2019, then plummeted by 113.71% to -$878000.0 in 2020.
- Its EBIT stands at -$878000.0 for Q4 2020, versus -$887000.0 for Q3 2020 and -$611000.0 for Q2 2020.